Peter D Emanuel

List of Publications by Year
in descending order

57	3,668	159358 30	182168 51
papers	citations	h-index	g-index

57	57	57	3997
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Sustained fetal hematopoiesis causes juvenile death from leukemia: evidence from a dual-ageâ€“specific mouse model. Blood Advances, 2020, 4, 3728-3740.	2.5	4
2	PTEN is indispensable for cells to respond to MAPK inhibitors in myeloid leukemia. Cellular Signalling, 2018, 50, 72-79.	1.7	6
3	Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects. Oncotarget, 2017, 8, 99161-99178.	0.8	53
4	Timing of the loss of Pten protein determines disease severity in a mouse model of myeloid malignancy. Blood, 2016, 127, 1912-1922.	0.6	15
5	Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2015, 62, 629-636.	0.8	43
6	Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia. Blood, 2015, 125, 516-524.	0.6	69
7	MYC amplification in multiple marker chromosomes and EZH2 microdeletion in a man with acute myeloid leukemia. Cancer Genetics, 2015, 208, 96-100.	0.2	2
8	The genomic landscape of juvenile myelomonocytic leukemia. Nature Genetics, 2015, 47, 1326-1333.	9.4	233
9	Proteasomeâ€associated autoinflammatory syndromes: advances in pathogeneses, clinical presentations, diagnosis, and management. International Journal of Dermatology, 2015, 54, 121-129.	0.5	74
10	Imatinib 800Âmg daily induces deeper molecular responses than imatinib 400Âmg daily: results of <scp>SWOG</scp> S0325, an intergroup randomized <scp>PHASE II</scp> trial in newly diagnosed chronic phase chronic myeloid leukaemia. British Journal of Haematology, 2014, 164, 223-232.	1.2	56
11	Mutations in GATA2 are rare in juvenile myelomonocytic leukemia. Blood, 2014, 123, 1426-1427.	0.6	12
12	Hallway gossip between Ras and PI3K pathways. Blood, 2014, 123, 2751-2753.	0.6	2
13	Subclonal Mutations in SETBP1 Predict Relapse in Juvenile Myelomonocytic Leukemia. Blood, 2014, 124, 410-410.	0.6	0
14	Opposite Effects of M1 and M2 Macrophages on Hematopoietic Stem Cell Self-Renewal and Ex Vivo Expansion. Blood, 2014, 124, 2909-2909.	0.6	0
15	Timing of the Loss of Pten Is Critical in Determining the Disease Phenotype in Mice- a Mouse Model for Pediatric Mixed MDS/MPN. Blood, 2014, 124, 3585-3585.	0.6	0
16	A case of proteasome-associated auto-inflammatory syndrome with compound heterozygous mutations. Journal of the American Academy of Dermatology, 2013, 69, e29-e32.	0.6	21
17	Deficiency of CREB and over expression of miR-183 in juvenile myelomonocytic leukemia. Leukemia, 2013, 27, 1585-1588.	3.3	15
18	A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood, 2012, 120, 3898-3905.	0.6	154

#	Article	IF	Citations
19	PTEN transcript variants caused by illegitimate splicing in â€œagedâ€•blood samples and EBV-transformed cell lines. Human Genetics, 2010, 128, 609-614.	1.8	10
20	PTEN deficiency is a common defect in juvenile myelomonocytic leukemia. Leukemia Research, 2009, 33, 671-677.	0.4	37
21	Author's response to the comments on â€œPTEN deficiency is a common defect in juvenile myelomonocytic leukemiaâ€•[Leuk. Res. (2008) (Epub November 17)]. Leukemia Research, 2009, 33, 1580.	0.4	0
22	Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (TelintraÂ®, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. Journal of Hematology and Oncology, 2009, 2, 20.	6.9	48
23	Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood, 2009, 114, 1859-1863.	0.6	260
24	mrtlâ€”A translation/localization regulatory protein encoded within the human câ€‹myc locus and distributed throughout the endoplasmic and nucleoplasmic reticular network. Journal of Cellular Biochemistry, 2008, 105, 1092-1108.	1.2	16
25	Alterations in RNAâ€‹binding activities of IRESâ€‹regulatory proteins as a mechanism for physiological variability and pathological dysregulation of IGFâ€‹IR translational control in human breast tumor cells. Journal of Cellular Physiology, 2008, 217, 172-183.	2.0	49
26	Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Leukemia, 2008, 22, 1335-1342.	3.3	118
27	Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia. Blood, 2008, 111, 1124-1127.	0.6	33
28	RAS Pathway Mutations in Juvenile Myelomonocytic Leukemia. Acta Haematologica, 2008, 119, 207-211.	0.7	12
29	Drifting precariously due to lost tyrosines. Blood, 2007, 109, 7-8.	0.6	6
30	Mixed myeloproliferative and myelodysplastic disorders. Current Hematologic Malignancy Reports, 2007, 2, 9-12.	1.2	4
31	Diversity and Functional Consequences of Germline and Somatic PTPN11 Mutations in Human Disease. American Journal of Human Genetics, 2006, 78, 279-290.	2.6	352
32	Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies. Blood, 2006, 108, 1684-1689.	0.6	78
33	ActivatingFLT3 mutations are rare in children with juvenile myelomonocytic leukemia. Pediatric Blood and Cancer, 2005, 44, 142-146.	0.8	17
34	The ELAV RNA-stability factor HuR binds the 5'-untranslated region of the human IGF-IR transcript and differentially represses cap-dependent and IRES-mediated translation. Nucleic Acids Research, 2005, 33, 2962-2979.	6.5	104
35	The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood, 2005, 106, 2183-2185.	0.6	247
36	Phase II Window Study of the Farnesyltransferase Inhibitor R115777 (ZarnestraÂ®) in Untreated Juvenile Myelomonocytic Leukemia (JMML): A Childrenâ€™s Oncology Group Study.. Blood, 2005, 106, 2587-2587.	0.6	20

#	Article	IF	Citations
37	Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood, 2004, 103, 2325-2331.	0.6	415
38	Juvenile myelomonocytic leukemia. Psychophysiology, 2004, 3, 203-9.	1.1	49
39	The 5?-untranslated RNA of the human dhfr minor transcript alters transcription pre-initiation complex assembly at the major (core) promoter. Journal of Cellular Biochemistry, 2003, 88, 165-180.	1.2	54
40	Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia, 2003, 17, 1068-1077.	3.3	138
41	Inhibition of tumorigenicity by the 5â€²-untranslated RNA of the human c-myc P0 transcript. Experimental Cell Research, 2003, 288, 131-142.	1.2	12
42	Evidence for differential ribonucleoprotein complex assembly in vitro on the 5â€²-untranslated region of the human IGF-IR transcript. Molecular and Cellular Endocrinology, 2003, 200, 127-140.	1.6	5
43	Atypical Cellular Disorders. Hematology American Society of Hematology Education Program, 2002, 2002, 297-314.	0.9	31
44	Human Herpesvirus 6 Infection Mimicking Juvenile Myelomonocytic Leukemia in an Infant. The American Journal of Pediatric Hematology/oncology, 2002, 24, 136-141.	1.3	37
45	Targeting Raf-1 gene expression by a DNA enzyme inhibits juvenile myelomonocytic leukemia cell growth. Blood, 2002, 99, 4147-4153.	0.6	42
46	Purification and characterization of the yeast-expressed erythropoietin mutant Epo (R103A), a specific inhibitor of human primary hematopoietic cell erythropoiesis. Blood, 2002, 99, 4400-4405.	0.6	8
47	Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors. Blood, 2000, 95, 639-645.	0.6	59
48	Myelodysplasia and myeloproliferative disorders in childhood: an update. British Journal of Haematology, 1999, 105, 852-863.	1.2	76
49	Myelodysplasia and myeloproliferative disorders in childhood: an update. , 1999, 105, 852.		2
50	Conformationally Defined Retinoic Acid Analogues. 4. Potential New Agents for Acute Promyelocytic and Juvenile Myelomonocytic Leukemias. Journal of Medicinal Chemistry, 1998, 41, 1679-1687.	2.9	53
51	Mutations of the NF1 Gene in Children With Juvenile Myelomonocytic Leukemia Without Clinical Evidence of Neurofibromatosis, Type 1. Blood, 1998, 92, 267-272.	0.6	190
52	Juvenile Chronic Myelogenous Leukemia. American Journal of Clinical Pathology, 1996, 105, 238-248.	0.4	30
53	Juvenile myelomonocytic leukemia: molecular understanding and prospects for therapy. Trends in Molecular Medicine, 1996, 2, 468-475.	2.6	79
54	Sickle cell acute chest syndrome associated with parvovirus B19 infection: Case series and review. , 1996, 51, 207-213.		45

#	Article	IF	Citations
55	A Pilot Study of Isotretinoin in the Treatment of Juvenile Chronic Myelogenous Leukemia. New England Journal of Medicine, 1994, 331, 1680-1684.	13.9	99
56	Cloning and sequencing of the cDNAs encoding two alternative splicing-derived variants of the alpha subunit of the granulocyte-macrophage colony-stimulating factor receptor. Biochimica Et Biophysica Acta - Molecular Cell Research, 1994, 1223, 306-308.	1.9	14
57	Valproic acid-induced cytopenias: Evidence for a dose-related suppression of hematopoiesis. Journal of Pediatrics, 1990, 117, 495-499.	0.9	60